JP6826983B2 - 胚移植 - Google Patents
胚移植 Download PDFInfo
- Publication number
- JP6826983B2 JP6826983B2 JP2017539282A JP2017539282A JP6826983B2 JP 6826983 B2 JP6826983 B2 JP 6826983B2 JP 2017539282 A JP2017539282 A JP 2017539282A JP 2017539282 A JP2017539282 A JP 2017539282A JP 6826983 B2 JP6826983 B2 JP 6826983B2
- Authority
- JP
- Japan
- Prior art keywords
- vaginal
- recombinant
- csf
- pessary
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/02—Instruments or methods for reproduction or fertilisation for artificial insemination
- A61D19/022—Containers for animal semen, e.g. pouches or vials ; Methods or apparatus for treating or handling animal semen containers, e.g. filling or closing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
(i)本発明の組成物を含む少なくとも1つの膣送達ビヒクルを雌の膣内に導入すること、
(ii)任意選択で、さらなる膣送達ビヒクルを挿入すること、
(iii)膣送達ビヒクルの活性成分が放出され、膣内に浸透して経粘膜的に吸収され、ならびに/または拡散し、ならびに/または子宮内におよび/もしくは胃腸管粘膜を介して輸送されるのに十分な時間を経過させること、ならびに
(iv)雄と交尾させること、または、人工授精、ドナー配偶子、もしくは胚もしくは他の同種移植片を移植のために子宮内に導入することのいずれかによって、雌を授精させること
を含む、方法が提供される。
(i)本発明の組成物を含む少なくとも1つの膣送達ビヒクルを雌の膣内に導入すること、
(ii)任意選択で、さらなる膣送達ビヒクルを挿入すること、
(iii)膣送達ビヒクルの活性成分が放出され、膣内に浸透して経粘膜的に吸収され、ならびに/または拡散し、ならびに/または子宮内におよび/もしくは胃腸管粘膜を介して輸送されるのに十分な時間を経過させること、ならびに
(iv)雄と交尾させること、または、人工授精、ドナー配偶子、もしくは胚もしくは他の同種移植片を移植のために子宮内に導入することのいずれかによって、雌を授精させること
を含む、方法が提供される。
性的に成熟したCD1雄マウス(n=20)およびWistarラット(n=20)を屠殺し、死後、精嚢腺から精液を採取した。死後のアプローチを選択して電気射精による試料採取を回避したが、これは、この方法では精子の質が変わりやすく、また試料が急速に凝固して分析に問題が生じるためである。貯精嚢の試料採取が理想的であるが、これは、(付属腺のものよりも)この液の方が調査対象の母体系の免疫調節因子を含んでおり、また、腺分泌物の凝固をより容易に回避することができるためである。
Claims (10)
- 組み換え体IL−12および組み換え体GM−CSFからなり、前記組み換え体IL−12および組み換え体GM−CSFを、生殖能力のある雄の精液中に見られるIL−12およびGM−CSFに相当する生理学的濃度範囲内で膣内でインサイチュで放出するように構成されている、胚の移植前または授精前に雌において妊娠率の改善に使用するための組成物。
- 組み換え体IL−12がIL−12p40またはIL−12p70のいずれかである、請求項1に記載の組成物。
- 組み換え体IL−12および組み換え体GM−CSFからなり、膣挿入物であり、前記組み換え体IL−12および組み換え体GM−CSFを、生殖能力のある雄の精液中に見られるIL−12およびGM−CSFに相当する生理学的濃度範囲内で膣内でインサイチュで放出するように構成されている、胚の移植前または授精前に雌において妊娠率の改善に使用するための医薬組成物。
- 組み換え体IL−12および組み換え体GM−CSFが、生殖能力のある雄の精液中に見られるそれらの近似の生理学的範囲内またはその範囲以上でのいずれかでインサイチュで放出されるように構成されている、請求項3に記載の医薬組成物。
- 膣挿入物が、膣用カプセル、膣用ゲル、膣用錠、膣用粉末、膣用溶液、膣用ペッサリー、膣用カップ、膣用スポンジ、膣用エアロゾル、または膣用フォームもしくはスプレーである、請求項3または4のいずれかに記載の医薬組成物。
- 医薬組成物が、迅速送達、制御送達、連続送達、またはパルス送達製剤である、請求項5に記載の医薬組成物。
- 妊娠率の改善に使用するための、請求項1または2のいずれかに記載の組成物を含む経粘膜膣送達用のペッサリー。
- げっ歯類における子宮の受容性を助長させるための、請求項7に記載のペッサリー。
- げっ歯類がマウスまたはラットである、請求項8に記載のペッサリー。
- 請求項1または2のいずれかに記載の組成物、請求項3から6のいずれかに記載の医薬組成物、または請求項7から9のいずれかに記載のペッサリーを含む膣送達ビヒクルと、キットに含まれるときに前記膣送達ビヒクルをレシピエントの雌の膣に挿入するための装置とを含む、キット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562108222P | 2015-01-27 | 2015-01-27 | |
US62/108,222 | 2015-01-27 | ||
GBGB1501302.2A GB201501302D0 (en) | 2015-01-27 | 2015-01-27 | Embryo implantation |
GB1501302.2 | 2015-01-27 | ||
PCT/GB2016/050175 WO2016120617A1 (en) | 2015-01-27 | 2016-01-27 | Embryo implantation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018507189A JP2018507189A (ja) | 2018-03-15 |
JP2018507189A5 JP2018507189A5 (ja) | 2019-03-07 |
JP6826983B2 true JP6826983B2 (ja) | 2021-02-10 |
Family
ID=52673965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017539282A Active JP6826983B2 (ja) | 2015-01-27 | 2016-01-27 | 胚移植 |
Country Status (13)
Country | Link |
---|---|
US (2) | US10293029B2 (ja) |
EP (1) | EP3250224B1 (ja) |
JP (1) | JP6826983B2 (ja) |
CN (1) | CN107206054B (ja) |
AU (1) | AU2016210988B2 (ja) |
CA (1) | CA2973793A1 (ja) |
DK (1) | DK3250224T3 (ja) |
ES (1) | ES2790743T3 (ja) |
GB (2) | GB201501302D0 (ja) |
PL (1) | PL3250224T3 (ja) |
PT (1) | PT3250224T (ja) |
SG (1) | SG11201705851RA (ja) |
WO (1) | WO2016120617A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
CN113584180B (zh) * | 2021-07-06 | 2024-02-06 | 浙江大学 | 子宫内膜来源的外分泌体miRNA在胚胎着床中的应用 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS563846B2 (ja) | 1972-10-12 | 1981-01-27 | ||
US4211769A (en) | 1977-08-24 | 1980-07-08 | Takeda Chemical Industries, Ltd. | Preparations for vaginal administration |
AU4652596A (en) | 1995-01-09 | 1996-07-31 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
AUPO550897A0 (en) | 1997-03-06 | 1997-03-27 | Luminis Pty Limited | Treatment and diagnosis of an infertility condition |
EP1126843A4 (en) | 1998-10-29 | 2005-06-15 | Bristol Myers Squibb Co | AMINO-CELL DERIVATIVE COMPOUNDS INHIBITORS OF ENZYME IMPDH |
US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
US6627651B1 (en) | 1999-05-07 | 2003-09-30 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
KR100760434B1 (ko) | 1999-09-17 | 2007-10-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 벤즈아미드 및 관련된 Xa 인자의 억제제 |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
US20090124690A1 (en) | 2000-04-03 | 2009-05-14 | Alberte Randall S | Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins |
WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
US7173113B2 (en) | 2002-01-31 | 2007-02-06 | The Trustees Of Columbia University In The City Of New York | Long-acting hormone and growth factor compositions and uses thereof |
WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4アンタゴニストおよびその医薬用途 |
AU2002951531A0 (en) | 2002-09-20 | 2002-10-03 | The University Of Adelaide | Treatment and diagnosis of an infertility condition by measuring or inhibiting interferon-y |
AU2003300126B2 (en) | 2002-12-31 | 2010-04-01 | Altus Pharmaceuticals Inc. | Complexes of protein crystals and ionic polymers |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
CN101123977A (zh) * | 2003-03-25 | 2008-02-13 | 海里康公司 | 用于诱导治疗应答的组合物 |
US7323346B2 (en) | 2003-08-14 | 2008-01-29 | The General Hospital Corporation | Screening for gestational disorders |
EP1684782B1 (en) | 2003-10-03 | 2015-09-30 | Thorn BioScience, LLC | Process for the synchronization of ovulation for timed breeding without heat detection |
US7723290B2 (en) | 2004-10-22 | 2010-05-25 | Bioincept, Llc | Compositions and methods for modulating the immune system |
US8338373B2 (en) | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
WO2005115456A2 (en) | 2004-05-28 | 2005-12-08 | President And Fellows Of Harvard College | METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY |
PT1753456T (pt) | 2004-06-10 | 2016-11-04 | Univ Leicester | Métodos para tratar condições associadas com a ativação do complemento dependente de masp-2 |
US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
CN100381460C (zh) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
CN103285392A (zh) * | 2005-04-26 | 2013-09-11 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和其用途 |
WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
US7790463B2 (en) | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
WO2007113682A2 (en) | 2006-04-06 | 2007-10-11 | Novozymes Gropep Ltd | Tgf-beta pharmaceutical compositions |
US9625453B2 (en) | 2006-11-28 | 2017-04-18 | Pictor Limited | Assay membrane and method of use thereof |
NZ578180A (en) | 2006-12-08 | 2012-02-24 | Millennium Pharm Inc | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
WO2008070902A1 (en) | 2006-12-11 | 2008-06-19 | Novozymes Biopharma Au Limited | Tgf-beta compositions for treating infertility |
US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
AU2008277730B2 (en) | 2007-07-13 | 2013-01-31 | Addex Pharma S.A. | Pyrazole derivatives as modulators of metabotropic glutamate receptors |
WO2009010871A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as antagonists of adenosine a3 receptor |
JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
DK2183254T3 (en) | 2007-08-29 | 2017-09-11 | Methylgene Inc | INHIBITORS OF PROTEINTYROSINKINASE ACTIVITY |
US8003324B2 (en) | 2007-10-18 | 2011-08-23 | U.S. Department Of Veterans Affairs | Modulation of sodium channels by nicotinamide adenine dinucleotide |
GB0806281D0 (en) | 2008-04-07 | 2008-05-14 | Univ Leeds | Markers of Oocyte viability |
EP2274325A4 (en) | 2008-05-13 | 2011-05-25 | Nora Therapeutics Inc | ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
WO2010126528A1 (en) | 2009-05-01 | 2010-11-04 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
CA2763123A1 (en) | 2009-06-18 | 2010-12-29 | Cellartis Ab | 3d culturing systems for growth and differentiation of human pluripotent stem (hps) cells |
US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
CA2770140A1 (en) | 2009-08-05 | 2011-02-10 | Yitsun Richard Kao | Antiviral compounds and methods of making and using thereof cross reference to related applications |
WO2011143752A1 (en) | 2010-05-20 | 2011-11-24 | University Of Saskatchewan | Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal |
CA2801182A1 (en) | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2012079032A2 (en) | 2010-12-09 | 2012-06-14 | Trana Discovery, Inc. | Compositions and methods of treating drug-resistant retroviral infections |
US20140031547A1 (en) | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
US8518879B2 (en) * | 2011-03-04 | 2013-08-27 | Ahmed H. Al-Qahtani | Skin cream |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
ITTO20111183A1 (it) | 2011-12-21 | 2013-06-22 | Univ Degli Studi Torino | Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia |
ITMI20122063A1 (it) | 2012-12-03 | 2014-06-04 | Marco Sbracia | Gm-csf per l'utilizzo nella prevenzione dell'aborto spontaneo e del fallimento dell'impianto dell'embrione |
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
US20160375090A1 (en) | 2013-11-27 | 2016-12-29 | Jbs United Animal Health Ii Llc | Method and composition for synchronizing time of insemination in gilts |
GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
-
2015
- 2015-01-27 GB GBGB1501302.2A patent/GB201501302D0/en not_active Ceased
-
2016
- 2016-01-27 ES ES16702975T patent/ES2790743T3/es active Active
- 2016-01-27 DK DK16702975.0T patent/DK3250224T3/da active
- 2016-01-27 EP EP16702975.0A patent/EP3250224B1/en active Active
- 2016-01-27 PL PL16702975T patent/PL3250224T3/pl unknown
- 2016-01-27 JP JP2017539282A patent/JP6826983B2/ja active Active
- 2016-01-27 GB GB1601505.9A patent/GB2539986B/en not_active Expired - Fee Related
- 2016-01-27 CA CA2973793A patent/CA2973793A1/en not_active Abandoned
- 2016-01-27 WO PCT/GB2016/050175 patent/WO2016120617A1/en active Application Filing
- 2016-01-27 CN CN201680007123.5A patent/CN107206054B/zh not_active Expired - Fee Related
- 2016-01-27 SG SG11201705851RA patent/SG11201705851RA/en unknown
- 2016-01-27 US US15/007,795 patent/US10293029B2/en not_active Expired - Fee Related
- 2016-01-27 AU AU2016210988A patent/AU2016210988B2/en not_active Ceased
- 2016-01-27 PT PT167029750T patent/PT3250224T/pt unknown
-
2019
- 2019-03-22 US US16/361,296 patent/US10987406B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10987406B2 (en) | 2021-04-27 |
AU2016210988A1 (en) | 2017-08-17 |
US20190216896A1 (en) | 2019-07-18 |
GB201601505D0 (en) | 2016-03-09 |
GB201501302D0 (en) | 2015-03-11 |
PT3250224T (pt) | 2020-05-18 |
PL3250224T3 (pl) | 2020-07-13 |
US20160213749A1 (en) | 2016-07-28 |
JP2018507189A (ja) | 2018-03-15 |
WO2016120617A1 (en) | 2016-08-04 |
GB2539986B (en) | 2017-07-12 |
AU2016210988B2 (en) | 2021-04-29 |
GB2539986A (en) | 2017-01-04 |
SG11201705851RA (en) | 2017-08-30 |
CA2973793A1 (en) | 2016-08-04 |
EP3250224A1 (en) | 2017-12-06 |
EP3250224B1 (en) | 2020-04-22 |
US10293029B2 (en) | 2019-05-21 |
CN107206054B (zh) | 2021-08-20 |
DK3250224T3 (da) | 2020-05-18 |
ES2790743T3 (es) | 2020-10-29 |
CN107206054A (zh) | 2017-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wongtawan et al. | Fertility after deep intra-uterine artificial insemination of concentrated low-volume boar semen doses | |
Rath | Low dose insemination in the sow–a review | |
TANAKA et al. | Artificial intravaginal insemination using fresh semen in cats | |
CN105555298B (zh) | 胚胎植入 | |
Sharman | Marsupial reproduction | |
JP2018531940A (ja) | 繁殖を管理するための方法および組成物 | |
US10987406B2 (en) | Embryo implantation | |
Sontakke | Monitoring and controlling ovarian activities in wild ungulates | |
Johnston et al. | The koala (Phascolarctos cinereus): a case study in the development of reproductive technology in a marsupial | |
Johnston et al. | Using the koala (Phascolarctos cinereus) as a case study to illustrate the development of artificial breeding technology in marsupials: an update | |
Gonzalez-Ramiro et al. | A short-term altrenogest treatment post-weaning followed by superovulation reduces pregnancy rates and embryo production efficiency in multiparous sows | |
Crosier et al. | Reproductive physiology of the cheetah and assisted reproductive techniques | |
Felix | Conception and gestation in domestic animals and various factors influencing them: a review | |
Faria et al. | Fixed-time artificial insemination in the bovine'Lydia Brava dos Açores' using frozen semen. | |
Priskas et al. | Factors affecting pregnancy rate after cervical insemination in dairy sheep flocks | |
Timothy Smith et al. | Distribution and Number of Spermatozoa in the Oviduct of the Golden Hamster after Natural Mating and Artificial Insemination | |
TOMPKINS | The effects of elevated ambient temperatures on embryonic mortality in swine and rats | |
Proháczik | Sexual endocrine diagnostic and treatment methods in the domestic ferret (Mustela putorius furo) | |
OVULATION | 1 OVINE SERIC AND PITUITARY ISOFORMS OF LUTEINISING HORMONE DURING DIESTRUS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190121 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191025 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200828 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6826983 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |